Evidence map›Paper›PMID 42127430›Full record

ArticleHepatology (Baltimore, Md.)2026

Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH.

Naga Chalasani, Erik J Tillman, Sonja K Billes, Timothy Rolph, Mazen Noureddin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology (Baltimore, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Naga ChalasaniDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0003-4082-3178
Erik J TillmanAkero Therapeutics, a Novo Nordisk company, South San Francisco, California, USA.ORCID 0000-0003-3599-0297
Sonja K BillesAkero Therapeutics, a Novo Nordisk company, South San Francisco, California, USA.ORCID 0000-0001-7042-9142
Timothy RolphAkero Therapeutics, a Novo Nordisk company, South San Francisco, California, USA.ORCID 0000-0001-5284-6903
Mazen NoureddinSherrie & Alan Conover Center for Liver Disease & Transplantation, Underwood Center for Digestive Disorders, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0003-2127-2040

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cirrhosisFGF21fibrosismetabolic dysfunction–associated steatohepatitistreatment

Identifiers

PMID42127430
PMCPMC13374643

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.